



# Activation of Human NK Cells by *Bordetella pertussis* Requires Inflammasome Activation in Macrophages

Michiel M. Kroes<sup>1,2</sup>, Rob Mariman<sup>1</sup>, Daniëlle Hijdra<sup>1</sup>, Hendrik-Jan Hamstra<sup>1</sup>, Karlijn J. W. M. van Boxtel<sup>1</sup>, Jos P. M. van Putten<sup>2</sup>, Jelle de Wit<sup>1</sup> and Elena Pinelli<sup>1\*</sup>

<sup>1</sup> Center for Immunology of Infectious Diseases and Vaccines, Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands, <sup>2</sup> Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands

## OPEN ACCESS

### Edited by:

Daniel M. Altmann,  
Imperial College London,  
United Kingdom

### Reviewed by:

Paras K. Anand,  
Imperial College London,  
United Kingdom  
Françoise Mascart,  
Free University of Brussels, Belgium

### \*Correspondence:

Elena Pinelli  
elena.pinelli.ortiz@rivm.nl

### Specialty section:

This article was submitted to  
Microbial Immunology,  
a section of the journal  
Frontiers in Immunology

**Received:** 26 March 2019

**Accepted:** 12 August 2019

**Published:** 27 August 2019

### Citation:

Kroes MM, Mariman R, Hijdra D, Hamstra H-J, van Boxtel KJWM, van Putten JPM, de Wit J and Pinelli E (2019) Activation of Human NK Cells by *Bordetella pertussis* Requires Inflammasome Activation in Macrophages. *Front. Immunol.* 10:2030. doi: 10.3389/fimmu.2019.02030

Pertussis is a highly contagious respiratory infection caused by the bacterium *Bordetella pertussis*. Humans are the only known natural reservoir of *B. pertussis*. In mice, macrophages and NK cells have a key role in confining *B. pertussis* to the respiratory tract. However, the mechanisms underlying this process, particularly during human infections, remain unclear. Here we characterized the activation of human macrophages and NK cells in response to *B. pertussis* and unraveled the role of inflammasomes in this process. NLRP3 inflammasome activation by *B. pertussis* in human macrophage-like THP-1 cells and primary monocyte-derived macrophages (mo-MΦ) was shown by the visualization of ASC-speck formation, pyroptosis, and the secretion of caspase-mediated IL-1β and IL-18. In contrast to macrophages, stimulation of human CD56<sup>+</sup>CD3<sup>-</sup> NK cells by *B. pertussis* alone did not result in activation of these cells. However, co-culture of *B. pertussis*-stimulated mo-MΦ and autologous NK cells resulted in high amounts of IFNγ secretion and an increased frequency of IL-2Rα<sup>+</sup> and HLA-DR<sup>+</sup> NK cells, indicating NK cell activation. This activation was significantly reduced upon inhibition of inflammasome activity or blocking of IL-18 in the mo-MΦ/NK cell co-culture. Furthermore, we observed increased secretion of proinflammatory cytokines in the *B. pertussis*-stimulated mo-MΦ/NK co-culture compared to the mo-MΦ single culture. Our results demonstrate that *B. pertussis* induces inflammasome activation in human macrophages and that the IL-18 produced by these cells is required for the activation of human NK cells, which in turn enhances the pro-inflammatory response to this pathogen. Our data provides a better understanding of the underlying mechanisms involved in the induction of innate immune responses against *B. pertussis*. These findings contribute to the knowledge required for the development of improved intervention strategies to control this highly contagious disease.

**Keywords:** inflammasome, NLRP3, crosstalk, interferon-gamma, interleukin-18, innate immunity, *Bordetella pertussis*, human

## INTRODUCTION

Pertussis, also known as whooping cough, is a highly contagious and acute disease of the upper respiratory tract, which can be fatal in newborns and non-vaccinated young children. Pertussis is caused by the Gram-negative bacterium *Bordetella pertussis* (1, 2) and humans are the only known natural reservoir for this pathogen (3). Despite pertussis being a vaccine preventable disease, it has reemerged in vaccinated populations (4, 5). Proposed reasons for this reemergence include pathogen adaptation and waning of vaccine-induced immunity (6–8). Prevention and control of this disease requires new and improved intervention strategies for which a better understanding of the underlying mechanisms involved in shaping a protective immune response is crucial.

The innate immune system is the first line of defense against invading microorganisms. Upon activation, it immediately combats microbes and additionally orchestrates an adaptive immune response. Innate immune cells, including dendritic cells (DCs) and macrophages, contribute to *B. pertussis* induced immunity (9–11). Sensing of *B. pertussis* by murine DCs and macrophages has been shown to result in inflammasome activation (9, 12). Inflammasomes are multiprotein complexes that form in the cytosol of immune cells, particularly in macrophages (13, 14). The best characterized inflammasomes are composed of a specific sensor protein of the nucleotide-binding oligomerization domain-like receptor (NLR) family, the apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC) adaptor protein and pro-caspase-1 (15). Activation of the sensor protein results in the formation of a single, compact speck by the ASC protein, which is essential for the oligomerization and activation of caspase-1 (16). Active caspase-1 cleaves pro-IL-1 $\beta$  and pro-IL-18 resulting in the release of bioactive IL-1 $\beta$  and IL-18, and induces pyroptosis, a form of proinflammatory cell death (17–19). In mice, inflammasome activation is associated with the induction of an antigen-specific T helper (Th) 17 response and clearance of the pathogen (9, 12). Whether *B. pertussis* induces inflammasome activation in human cells and whether this enhances the immune responses against this pathogen is unknown.

Another innate immune cell that has been shown to be essential in the clearance of *B. pertussis* is the natural killer (NK) cell. In mice lacking NK cells, *B. pertussis* disseminates from the respiratory tract and causes a lethal infection (20, 21). One of the main functions of NK cells during bacterial infections is the secretion of the proinflammatory cytokine IFN $\gamma$  (22). Disruption of IFN $\gamma$  signaling during a murine infection with *B. pertussis* results in a lethal disseminating disease (21). Furthermore, IFN $\gamma$  enhances the killing of *B. pertussis* by murine macrophages (23). These studies imply an essential role for IFN $\gamma$  secreting NK cells in the protective immune response against *B. pertussis* in the mouse model. However, the mechanism by which NK cells are activated during *B. pertussis* infection and how the secretion of IFN $\gamma$  is induced is unknown in mice and humans.

Since inflammasome activation in macrophages results in the secretion of IL-18 and this cytokine is known to activate NK cells (24–27), we investigate the potential crosstalk between human

macrophages and NK cells in response to *B. pertussis* and the role of inflammasomes in this process. We show for the first time that *B. pertussis* induces inflammasome activation in human macrophages and that caspase-mediated IL-18 release is required for the activation of NK cells by the pathogen.

## MATERIALS AND METHODS

### Ethics Statement

This study was conducted according to the principles described in the Declaration of Helsinki. Buffy coats were provided by the Sanquin Blood Supply. For the collection of samples and subsequent analyses, all blood donors provided written informed consent. Blood samples were processed anonymously and the research goal, primary cell isolation, required no review by an accredited Medical Research Ethics Committee, as determined by the Dutch Central Committee on Research involving human subjects.

### Culture Media

THP-1 cells (InvivoGen) were cultured in Roswell Park Memorial Institute 1640 medium (RPMI; Gibco) enriched with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 29.2  $\mu$ g/ml L-Glutamine (Gibco), and 100  $\mu$ g/ml Normocin<sup>TM</sup> (InvivoGen), from here on referred to as RPMI culture medium. NK cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% FBS, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 29.2  $\mu$ g/ml L-Glutamine, from here on referred to as IMDM culture medium. Monocytes were differentiated to macrophages in IMDM supplemented with 1% FBS, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 29.2  $\mu$ g/ml L-Glutamine, and 50 U/ml human GM-CSF (PreproTech), from here on referred to as monocyte differentiation medium. mo-M $\Phi$  and mo-M $\Phi$ /NK co-cultures were stimulated in IMDM medium enriched with 1% FBS and 29.2  $\mu$ g/ml L-Glutamine (Lonza), from here on referred to as infection medium. HEK-Blue IL-1R and HEK-Blue-Null1 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco) enriched with 10% FBS, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, 100  $\mu$ g/ml Normocin<sup>TM</sup>, and 29.2  $\mu$ g/ml L-Glutamine, from here on referred to as HEK-Blue culture medium.

### Bacterial Strains and Growth Conditions

The streptomycin and nalidixic acid resistant *B. pertussis* Tohama I derivative, B0213, and a *B. pertussis* clinical isolate from 2015, B4393, were used in this study. To ensure consistency in bacterial inoculates between experiments, flash freeze vials (FFV) of both strains were prepared. To prepare the FFV, the bacteria were plated on Bordet Gengou (BG) agar plates, supplemented with 1% glycerol and 15% defibrinated sheep blood (BD Bioscience) and incubated at 35°C and 5% CO<sub>2</sub> for 4 days. Next, bacteria were sequentially passaged on two successive days on BG agar plates and incubated at 35°C and 5% CO<sub>2</sub> for 1 day. Bacteria were collected from the BG agar plates and suspended and extensively washed in Thalen-IJssel medium (28). Bacterial suspensions were prepared at OD<sub>590</sub> 0.5 in Thalen-IJssel medium supplemented

with 15% glycerol and snap frozen prior to storing at  $-80^{\circ}\text{C}$ . After thawing, FFV were spun down for 10 min at  $16,000 \times g$  and the pellet was suspended in infection medium prior to use for cellular *in vitro* infection. To ensure that the freezing process did not affect bacterial viability, colony forming units were confirmed on BG agar plates.

### THP-1 Cell Culture

The THP-1, THP-1 ASC-GFP, and THP-1 NLRP3 deficient cell lines (InvivoGen) were cultured in RPMI culture medium at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$ . Every other passage selective antibiotics, 100  $\mu\text{g}/\text{ml}$  Zeocin<sup>TM</sup> (InvivoGen) for THP-1 ASC-GFP and 200  $\mu\text{g}/\text{ml}$  Hygromycin B Gold (InvivoGen) for NLRP3 deficient THP-1, were added to the RPMI culture medium.

### Human Monocyte and NK Cell Isolation and Macrophage Differentiation

Buffy coats from healthy human donors were used for the isolation of  $\text{CD}56^+\text{CD}3^-$  NK cells and  $\text{CD}14^+$  monocytes for the subsequent generation of mo-M $\Phi$ . First, peripheral blood mononuclear cells (PBMC) were obtained by gradient centrifugation of buffy coats diluted eight times in PBS at  $1,000 \times g$  for 30 min on Lymphoprep (Nycomed). PBMC were either frozen at  $-80^{\circ}\text{C}$  in 50% IMDM culture medium, 10% dimethylsulfoxide (DMSO; Sigma), and 40% FBS for later isolation of NK cells or were used for monocyte isolation using magnetically activated cell sorting in combination with anti-CD14 microbeads (Miltenyi Biotec). The purity of the CD14 positive cells was determined by flow cytometry. For this, monocytes were stained with anti-CD14-PE (BD Biosciences) followed by data acquisition on the LSRFortessa X-20 (BD Biosciences). Data analysis was performed using FlowJo software (version 10.5.3; Tree Star). Monocyte purity was more than 90% for every donor. To facilitate differentiation to mo-M $\Phi$ , monocytes were cultured in flat-bottom 96-well culture plates (Greiner) at 150,000 cells/well in monocyte differentiation medium, at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$  for 6 days. Monocyte differentiation medium was refreshed after 3 days. NK cells were isolated from the frozen PBMC fraction using the NK Cell Isolation Kit human (Miltenyi Biotec). The purity of the NK cells was determined by flow cytometry. NK cells were stained with anti-CD56-PE/Cy7 (BioLegend) and anti-CD3-BUV395 (BD Biosciences) followed by data acquisition on the LSRFortessa X-20 (BD Biosciences). Data analysis was performed using the FlowJo software (Tree Star). NK cell ( $\text{CD}56^+\text{CD}3^-$ ) purity was more than 90% for every donor.

### THP-1 Cell Stimulation

THP-1 cells were seeded into flat-bottom 96-well plates at 50,000 cells/well in RPMI culture medium containing 50 ng/ml Phorbol 12-myristate 13-acetate (InvivoGen) to induce differentiation toward a macrophage (M $\Phi$ )-like phenotype. After a 22 h incubation at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$ , cells were washed and incubated in RPMI culture medium for 3 additional days. M $\Phi$ -like THP-1 cells were incubated with the indicated amounts of Tohama I. As a positive control for NLRP3 inflammasome activation M $\Phi$ -like THP-1 cells were primed for 3 h with 100 ng/ml

LPS-EK (InvivoGen) and stimulated with 5  $\mu\text{g}/\text{ml}$  Nigericin (InvivoGen) for an additional 22 h. When indicated, M $\Phi$ -like THP-1 cells were stimulated in the presence of 10  $\mu\text{g}/\text{ml}$  of the caspase inhibitor, Z-VAD-FMK (InvivoGen). Stimulations were performed at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$  for 22 h after which supernatant was collected for further analysis.

### Mo-M $\Phi$ Stimulation

Mo-M $\Phi$  were stimulated with Tohama I or the clinical strain B4393 at a multiplicity of infection (MOI) of 10 in IMDM infection medium. When indicated, mo-M $\Phi$  were incubated with 20  $\mu\text{g}/\text{ml}$  caspase inhibitor for 30 min and subsequently stimulated with *B. pertussis* in the presence of 10  $\mu\text{g}/\text{ml}$  caspase inhibitor. Stimulations were performed at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$  for 22 h after which supernatant was collected for cytokine detection.

### NK Cell Stimulation

NK cells were seeded into round-bottom 96-wells plates (Greiner) at 150,000 cells/well in IMDM culture medium supplemented with 5 ng/ml recombinant human IL-15 (rhIL-15; PeproTech) (29). Next, NK cells were immediately stimulated with *B. pertussis* B4393 at a MOI of 10 in the presence or absence of 5 ng/ml recombinant human IL-18 (rhIL-18; R&D systems), 10 ng/ml rhIL-6 (Miltenyi Biotec), 10 ng/ml rhTNF $\alpha$  (PeproTech), or 10 ng/ml rhIL-1 $\beta$  (InvivoGen). Stimulations were performed at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$  for 18 h after which BD GolgiPlug<sup>TM</sup> containing Brefeldin A (BD Biosciences) was added to the culture for 4 h, to inhibit cytokine secretion, before collecting the NK cells for flow cytometry analysis.

### Mo-M $\Phi$ /NK Co-culture

NK cells were rested for 22 h in IMDM culture medium supplemented with 5 ng/ml rhIL-15 and incubated at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$  to ensure maturation of the NK cells (29). Mature NK cells were added to autologous mo-M $\Phi$  in a 1:1 ratio. Co-cultures were stimulated with *B. pertussis* B4393 at a MOI of 10. When indicated, mo-M $\Phi$  were incubated with 20  $\mu\text{g}/\text{ml}$  caspase inhibitor, 2  $\mu\text{g}/\text{ml}$  anti human IL-18 (rhIL-18; InvivoGen), or 2  $\mu\text{g}/\text{ml}$  of the isotype control human IgA2 (hIgA2; InvivoGen) for 30 min prior to addition of NK cells in a 1:1 ratio and stimulation of the co-culture. Stimulations were performed at  $37^{\circ}\text{C}$  and 5%  $\text{CO}_2$  for 22 h after which supernatants were collected for cytokine detection and NK cells were collected by washing the wells with PBS for FACS analysis.

### Cytokine and LDH Release Analysis

IL-1 $\beta$  and IL-6 were measured in the supernatant of THP-1 cell cultures by using a Ready-SET-Go ELISA kit (eBioscience) according to the manufacturer's instructions. Immulon 2 HB flat-bottom 96-well plates (Thermo Fisher Scientific) were used for all ELISAs. Mature biologically active IL-1 $\beta$  was measured in the supernatant of THP-1 cell cultures by using the HEK-Blue IL-1 $\beta$  receptor (IL1R) cell line (InvivoGen). The HEK-Blue IL1R cell line and the parental HEK-Blue Null1 cell line contain an NF- $\kappa$ B-inducible secreted embryonic alkaline phosphatase (SEAP) reporter gene. IL-1 $\beta$  signaling via the IL1 receptor on the HEK-Blue IL1R leads to expression of SEAP, which activity can be

detected in the culture supernatants after adding the substrate Quanti-Blue (InvivoGen). To control for endogenous NF- $\kappa$ B activation, the parental HEK-Blue-Null1 cells (InvivoGen) were used. HEK-Blue IL1R and HEK-Blue-Null1 cells were seeded into flat-bottom 96-wells plates at 50,000 cells/well in HEK-Blue culture medium containing 10% supernatant derived from THP-1 cell cultures or 2 ng/ml rhIL-1 $\beta$  (InvivoGen), serving as a positive control. After a 22 h incubation at 37°C, supernatants were collected and the Quanti-Blue substrate was added. After 2 h of incubation with the substrate, the OD values, indicating SEAP activity, were measured at 639 nm. Measurements and data analysis were performed with a BioTek PowerWave 340, using Gen5 software (version 1.11; BioTek). The concentrations of the cytokines IL-1 $\beta$ , IL-18, IL-23, GM-CSF, IL-10, TNF $\alpha$ , IFN $\gamma$ , and Granzyme B in the supernatant from mo-M $\Phi$  and NK single- and co-cultures were determined using a ProcartaPlex Mix & Match luminex kit (Invitrogen) according to the manufacturer's instructions. Measurements and data analysis were performed with the Bio-Plex 200, using Bio-Plex Manager software (version 6.1; Bio-Rad Laboratories). LDH release was determined as an indicative of pyroptosis by using the CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega) according to the manufacturer's instructions.


### Inflammasome qPCR Array

mRNA levels of 84 genes associated with inflammasomes were quantified using the RT<sup>2</sup> Profiler<sup>TM</sup> PCR Array Human

Inflammasomes (QIAGEN) according to the manufacturer's instructions. In short, mo-M $\Phi$  were stimulated with *B. pertussis* at a MOI of 100 for 6 h after which the cells were lysed using QIAzol lysis reagents (QIAGEN) and stored at -80°C prior to RNA isolation using the RNeasy mini kit (QIAGEN) following the manufacturer's protocol. cDNA was synthesized from 200 ng total RNA using the RT<sup>2</sup> First Strand kit (QIAGEN) following the manufacturer's protocol. cDNA was used together with the RT<sup>2</sup> SYBR Green qPCR Mastermix (QIAGEN) in the RT<sup>2</sup> Profiler<sup>TM</sup> PCR Human Inflammasomes Array (QIAGEN) according to the manufacturer's instructions. Data was acquired on a StepOnePlus Real-Time PCR System (Applied Biosystems). Relative transcription levels were analyzed using the web-based software available on www.qiagen.com.

### Flow Cytometry Analysis

NK cells were stained with anti-CD56 PE/Cy7, anti-CD16 BV510, anti-CD25 BV421, anti-HLA-DR BV650, anti-CD69 APC (all from BioLegend), Fixable Viability Stain 780 (BD Biosciences), and anti-CD3 BUV395 (BD Biosciences) for 30 min at 4°C, followed by washing in FACS buffer [PBS pH 7.2; 0.5% BSA (Sigma); 2 mM EDTA (Merck)] and fixed with 2% paraformaldehyde (Merck). For the detection of NK cell-expressed cytokines, NK cells were permeabilized and fixed using the Fixation/Permeabilization Solution kit (BD Biosciences) following the manufacturer's protocol and stained with anti-IFN $\gamma$  AF700 (BioLegend). NK cells were analyzed for





marker expression on the LSRFortessa X-20 (BD Biosciences) and analyzed using FlowJo software (Tree Star).

## Flow Imaging

Mo-M $\Phi$  stimulated with the clinical *B. pertussis* strain (B4393) at MOI 100 for 22h were washed with PBS and incubated with StemPro™ Accutase™ Cell Dissociation Reagent (Thermo Fisher Scientific) to detach the cells. Detached mo-M $\Phi$  were washed with FACS buffer and permeabilized and fixed using the Fixation/Permeabilization Solution kit (BD Biosciences) following the manufacturer's protocol. Permeabilized mo-M $\Phi$  were stained with the ASC-specific antibody anti-TMS1 (Abcam) for 40 min at 4°C. After extensive washing with PermWash (BD Biosciences) mo-M $\Phi$  were stained with the secondary antibody Goat anti-Rabbit IgG H&L (Alexa Fluor 488) (Abcam) for 40 min at 4°C. ASC-speck formation was imaged using the ImageStream MARK II (Merck). Data was analyzed using the Image Data Exploration and Analysis software (Merck).


## Statistical Analysis

Statistical significance was calculated using GraphPad Prism software (version 7). A Wilcoxon matched-pairs signed rank test followed by a bonferroni correction was used. A *p*-value of <0.05 was considered statistically significant.

## RESULTS

### *B. pertussis* Induces NLRP3 Inflammasome Activation in Human Macrophage-Like THP-1 Cells

In order to determine whether *B. pertussis* can induce inflammasome activation in human macrophages, we first used the human cell line THP-1, which was differentiated toward a M $\Phi$ -like phenotype. Stimulation of these M $\Phi$ -like THP-1 cells with *B. pertussis* (Tohama I) for 22h resulted in a robust dose-dependent IL-1 $\beta$  secretion (Figure 1A). This response was inhibited in the presence of a caspase inhibitor (Z-VAD-FMK)



(Figure 1A). Complete inhibition of IL-1 $\beta$  secretion by the caspase inhibitor was observed when the M $\Phi$ -like THP-1 cells were stimulated with the lowest bacterial concentration (MOI 1). These findings indicate that IL-1 $\beta$  secretion induced by *B. pertussis* was mediated by inflammasome activation. Using an IL-1 $\beta$  bioassay we confirmed that the mature form of IL-1 $\beta$  was secreted by *B. pertussis*-stimulated M $\Phi$ -like THP-1 cells (Figure S1). Another hallmark of inflammasome activation is the induction of a form of programmed cell death, named pyroptosis. When the M $\Phi$ -like THP-1 cells were stimulated with *B. pertussis*, a caspase-mediated increase in the release of LDH, a measure for pyroptosis, by these cells was observed


(Figure 1B). The caspase inhibitor did not have an effect on caspase-independent activation of M $\Phi$ -like THP-1 cells by *B. pertussis*, as indicated by the unaffected secretion of IL-6 by these cells (Figure 1C).


To determine whether *B. pertussis* activates the NLRP3 inflammasome, NLRP3 deficient THP-1 cells were stimulated with *B. pertussis* (Tohama I) at a MOI 10. This yielded very low levels of IL-1 $\beta$  (<10 pg/ml) compared to the NLRP3 expressing THP-1 cell line (Figure 1D). Additionally, *B. pertussis* induced 76.8% cell death of the NLRP3 expressing M $\Phi$ -like THP-1 cells, indicated by LDH release, whereas only 12.8% cell death of the NLRP3 deficient M $\Phi$ -like THP-1 cells was observed (Figure 1E). Although the *B. pertussis*-stimulated NLRP3 deficient THP-1 cells showed a strong reduction in LDH release and abrogation of IL-1 $\beta$  secretion, these cells were still capable of secreting the inflammasome-independent pro-inflammatory cytokine IL-6 in response to this pathogen (Figure 1F). These findings show that the *B. pertussis*-induced IL-1 $\beta$  secretion and cell death of M $\Phi$ -like THP-1 cells is dependent on the NLRP3 inflammasome.

### *B. pertussis* Induces Inflammasome Activation in Primary Human Monocyte-Derived Macrophages

To determine whether *B. pertussis* could also induce inflammasome activation in primary human mo-M $\Phi$ , fully differentiated mo-M $\Phi$  were stimulated with *B. pertussis* (Tohama I) at a MOI of 100. We first measured the transcription levels of 84 inflammasome-associated genes in mo-M $\Phi$  from three different donors after 6 h stimulation with *B. pertussis* relative to untreated cells, using reverse transcriptase qPCR (Figure S2). In the *B. pertussis*-stimulated mo-M $\Phi$  a significant increase in the mRNA levels of, among others, transcription factor *NFKB1*, *IL1B*, and *IL6* was observed (Figure 2A). We then determined whether *B. pertussis* could induce IL-1 $\beta$  and IL-18 release by human primary cells by stimulating the mo-M $\Phi$  with *B. pertussis* (Tohama I) at a MOI 10. In the supernatant of *B. pertussis*-stimulated mo-M $\Phi$ , significantly increased levels of IL-1 $\beta$  (Figure 2B) and IL-18 (Figure 2C) were detected as compared to untreated mo-M $\Phi$ . In the presence of the caspase inhibitor, the secretion of both cytokines was reduced (Figures 2B,C).

To determine whether a recently circulating strain of *B. pertussis* was also able to induce inflammasome activation, human mo-M $\Phi$  were stimulated with the clinical *B. pertussis* isolate B4393. Figure 2D shows that this clinical *B. pertussis* isolate induces high levels of IL-1 $\beta$  which were inhibited in the presence of the caspase inhibitor, indicating inflammasome-dependent IL-1 $\beta$  secretion. Additionally, inflammasome assembly in mo-M $\Phi$  upon *B. pertussis* (B4393) stimulation was visualized by the formation of the ASC-speck as shown by flow cytometry imaging (Figure 2E). In the medium control, ASC is evenly distributed throughout the mo-M $\Phi$  as indicated by the completely green fluorescent cells, whereas, in the *B. pertussis*-stimulated mo-M $\Phi$  a compact ASC-speck is observed.





Further experiments were performed using this clinical *B. pertussis* isolate.

All together, these data indicate that *B. pertussis* is able to induce inflammasome activation in primary human mo-MΦ.


### IL-18 Primes Human NK Cells to Produce IFN $\gamma$ in Response to *B. pertussis*

Since NK cells have been shown to play a critical role in the clearance of *B. pertussis* from the murine respiratory tract, we aim to unravel mechanisms by which human NK cells are activated by the pathogen. Primary human NK cells, isolated from 10 different donors, stimulated with *B. pertussis* (B4393) showed some IFN $\gamma$  production (Figure 3). Stimulation of NK cells with the known activator IL-18 (24–27), resulted in an average of 10.2% IFN $\gamma^+$  NK cells ( $p = 0.004$ ). Interestingly, stimulation of NK cells with *B. pertussis* in the presence of rhIL-18 yielded a synergistic increase from 8.87 to 34.35% IFN $\gamma^+$  NK cells compared to stimulation in the absence of rhIL-18 ( $p = 0.004$ ) (Figure 3). When stimulating NK cells in the presence of other inflammatory cytokines namely, IL-6, TNF $\alpha$  or IL-1 $\beta$  with or without *B. pertussis*, no significant increase in IFN $\gamma$  production was observed (Figure S3). These data show that *B. pertussis* enhances IFN $\gamma$  secretion by IL-18-activated NK cells.

### Increased Proinflammatory Cytokine Secretion in *B. pertussis*-Stimulated mo-MΦ/NK Co-cultures

To determine the potential effects of crosstalk between mo-MΦ and NK cells during *B. pertussis* stimulation, we

characterized the cytokine profile of *B. pertussis*-stimulated mo-MΦ and NK cells cultured either separately or in co-culture. Stimulation of mo-MΦ with *B. pertussis* (B4393) resulted in a significant increase in the secretion of a wide range of cytokines, namely, IL-1 $\beta$ , IL-18, GM-CSF, IL-23, and IL-10 (Figures 4A–D,F). No significant increase in TNF $\alpha$  secretion was observed (Figure 4E). Interestingly, when mo-MΦ were stimulated with *B. pertussis* in the presence of equal amounts of autologous NK cells the secretion of all pro-inflammatory cytokines, IL-23, IL-1 $\beta$ , IL-18, GM-CSF, and TNF $\alpha$  increased (Figures 4A–E). The secretion of the anti-inflammatory cytokine IL-10 was not affected by the presence of NK cells (Figure 4F). These data indicate that, co-culture of NK cells and mo-MΦ induced a stronger pro-inflammatory cytokine response to *B. pertussis* compared to mo-MΦ stimulated alone. NK cells alone stimulated with *B. pertussis* did not result in the increased secretion of any of these cytokines compared to unstimulated NK cells (Figures 4A–F). However, in the *B. pertussis*-stimulated mo-MΦ/NK co-culture, secretion of the NK cell associated cytokine, IFN $\gamma$ , was significantly increased compared to the *B. pertussis*-stimulated NK single culture (Figure 5A). Comparable findings on IFN $\gamma$  secretion were observed when NK cells alone were stimulated with *B. pertussis* in the presence of rhIL-18 (Figure 3). Additionally, co-culture of mo-MΦ and NK cells resulted in an increased release of granzyme B (Figure 5B) as well as in the frequency of NK cells expressing IL-2R $\alpha$  (Figures 5C,D) and HLA-DR (Figures 5E,F), indicating NK cell activation. These results show that there is crosstalk between mo-MΦ and NK cells in response to *B. pertussis*.



**FIGURE 5** | *B. pertussis*-stimulated mo-MΦ activate human NK cells. Mo-MΦ and NK cell single cultures and mo-MΦ/NK co-cultures were stimulated with *B. pertussis* (B4393, MOI = 10, dashed bars) or left untreated (clear bars) for 22 h. Secreted levels of (A) IFN $\gamma$  and (B) Granzyme B were measured in the supernatant ( $n = 7$ ). NK cells were stained for (C,D) IL-2R $\alpha$  ( $n = 4$ ) and (E,F) HLA-DR ( $n = 6$ ) and the expression of these markers was analyzed on CD56<sup>+</sup>CD3<sup>-</sup> NK cells. (A–C,E) Results are expressed as medians with interquartile range. Black dots represent values of individual donors. (D,F) Results are expressed as dot plots of one representative donor. \* $p < 0.05$ .

## IL-18 Contributes to NK Cell Activation and IFN $\gamma$ Secretion in a *B. pertussis*-Stimulated mo-MΦ/NK Co-culture

To investigate the contribution of inflammasome activation in the *B. pertussis*-induced IFN $\gamma$  secretion and NK cell activation, mo-MΦ/NK co-cultures were stimulated with *B. pertussis* (B4393) in the presence of a caspase inhibitor. This resulted in a reduction of 72.2% in IFN $\gamma$  secretion relative to the cultures stimulated in the absence of a caspase inhibitor (Figure 6A). Additionally, the frequency of IL-2R $\alpha$ <sup>+</sup> NK cells was reduced by 27.8% (Figure 6B). To determine the role of IL-18 in the activation of NK cells and secretion of IFN $\gamma$ , mo-MΦ/NK co-cultures were stimulated with *B. pertussis* in the presence of an IL-18 blocking antibody. This resulted in a reduction of 69.8% of the secreted IFN $\gamma$  (Figure 6C) and a 34.2% reduction in the frequency of IL-2R $\alpha$ <sup>+</sup> NK cells (Figure 6D) whereas blocking IL-1 $\beta$  had no effect (Figure S4).


Taken together, these data show that *B. pertussis* induces inflammasome activation in human macrophages resulting in IL-18 secretion, which is required for the activation of human NK cells and secretion of IFN $\gamma$  upon encounter with this pathogen (Figure 7).

## DISCUSSION


In this study, we show for the first time that *B. pertussis* induces activation of the NLRP3 inflammasome in human macrophages and that secreted IL-18 is required for NK cell activation by the pathogen. Furthermore, we show that the crosstalk between these innate cells in response to *B. pertussis* leads to an enhanced proinflammatory response.

Activation of the inflammasome complex is an early immune response involved in the induction of protective immunity against many different pathogens (30, 31). Here, we show





using different approaches, that *B. pertussis* induces NLRP3 inflammasome formation in human macrophages resulting in caspase-mediated secretion of IL-1 $\beta$  and IL-18, as well as the induction of pyroptosis. In a study using murine DCs, *B. pertussis* was shown to induce activation of the NLRP3 inflammasome (9). The authors used modified variants of the adenylate cyclase toxin to show that this inflammasome activation was dependent on the pore forming ability of the adenylate cyclase toxin (9). Whether this virulence factor is also required for inflammasome activation in human innate cells remains to be determined. In another study in mice, Place et al. showed that IL-1 $\beta$  signaling is required for the clearance of *B. pertussis* and that the IL-1 $\beta$  is produced independent of caspase-1/caspase-11 (12). The authors suggest that an inflammasome-independent mechanism is involved in the *in vivo* secretion of IL-1 $\beta$  during a *B. pertussis* infection. In contrast to these findings, the same authors showed that *in vitro* the production of IL-1 $\beta$  by bone marrow-derived murine macrophages did require caspase-1. We show that in a human *in vitro* model, IL-1 $\beta$  production in response to *B. pertussis* involve both NLRP3 and caspase activity.



In addition to its role in innate immunity, inflammasome activation has been associated with the induction of a Th1/Th17 adaptive immune response (32–34), which are the protective type of T cell responses against *B. pertussis* (35–39). Using a murine infection model, IL-1 $\beta$  signaling was shown to be a critical step in promoting a protective Th17 response during *B. pertussis* infection (9) and to be essential in the clearance of *B. pertussis* (12). Whether inflammasome activation in human innate cells by *B. pertussis* contributes to polarization of the human adaptive response toward a Th1/Th17 phenotype remains to be investigated. In addition to IL-1 $\beta$ , we show that *B. pertussis*-stimulated human macrophages secrete IL-6 and IL-23, which are both associated with the induction of a Th17 response (40). These findings suggest that *B. pertussis*-stimulated human macrophages contribute to polarization toward a Th17 immune response.

A striking finding from our work is that the presence of IL-18 is required for activation of human NK cells and secretion of IFN $\gamma$  in response to *B. pertussis*. IL-18 stimulation of human NK cells has been shown to stabilize IFN $\gamma$  mRNA via the activation of mitogen-activated protein kinase p38 (27). This stabilization of IFN $\gamma$  mRNA is a maturation step to prime NK cells for the production of IFN $\gamma$  upon a secondary activation signal through stimulation of pattern recognition receptors (PRR) expressed on NK cells (41, 42). In accordance with this, Lauzon et al. showed that IL-2 treated human NK cells secreted IFN $\gamma$  upon stimulation with TLR2, TLR3, TLR4, or TLR5 ligands (41). *B. pertussis* has been shown to activate different PRRs (43, 44), suggesting that PRRs stimulation provides the secondary activation signal required for IL-18-primed NK cells to produce IFN $\gamma$  in response to *B. pertussis*.

Our results show that crosstalk between human macrophages and NK cells results in enhanced secretion of proinflammatory cytokines upon *B. pertussis* encounter. We highlight the critical role for inflammasome activity and IL-18 secretion

in the induction of IFN $\gamma$  secretion and NK cell activation in response to *B. pertussis*. Mahon et al. showed that IFN $\gamma$  treatment of *B. pertussis*-infected murine macrophages resulted in reduced intracellular bacterial counts (23). Similarly, IFN $\gamma$  has been shown to enhance the antimicrobial activity of human macrophages (45, 46) also against intracellular *B. pertussis* (47). Furthermore, studies in mice have shown the essential role for NK cells (20) and IFN $\gamma$  (21, 23) in confining *B. pertussis* to the respiratory tract. Byrne et al. showed that *B. pertussis* infection of NK cell-depleted mice resulted in a lethal disseminating disease. Furthermore, the absence of NK cells resulted in reduced *B. pertussis*-specific IFN $\gamma$  secretion and an increase in IL-5 secretion by spleen cells isolated 14 days after infection. This indicates a role for NK cells in skewing T cells toward a Th1 phenotype (20). Future studies should focus on the contribution of the cellular interplay between human macrophages and NK cells, or between other innate immune cells, in skewing T cell responses during *B. pertussis* infection. In addition to the increased secretion of pro-inflammatory cytokines in the *B. pertussis*-stimulated mo-M $\Phi$ /NK co-culture, we observed enhanced levels of the serine protease Granzyme B. This protease is released by cytotoxic cells, such as NK cells, and has been shown to kill bacteria such as *Escherichia coli*, *Listeria monocytogenes*, and *Mycobacteria tuberculosis* by cleaving electron transporters, oxidative stress defense proteins (48) and multiple proteins involved in protein synthesis as well as folding and degradation (49). Whether the Granzyme B in the *B. pertussis*-stimulated mo-M $\Phi$ /NK co-culture has a bactericidal effect on *B. pertussis* remains to be elucidated.

Taken together, our data provides a better understanding of the underlying mechanisms involved in the induction of innate immune responses against *B. pertussis*. Highlighted is the importance of the crosstalk between human macrophages and NK cells in enhancing proinflammatory responses against this pathogen and the role for inflammasome activation in this process. Knowledge on the mechanisms involved in the induction of protective immunity against *B. pertussis* is required for the development of improved intervention strategies to control this highly contagious disease.

## REFERENCES

1. Diavatopoulos D, Cummins CA, Schouls LM, Brinig MM, Relman DA, Mooi FR. *Bordetella pertussis*, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of *B. bronchiseptica*. *PLoS Pathog.* (2005) 1:11. doi: 10.1371/journal.ppat.0010045
2. Melvin JA, Scheller EV, Miller JE, Cotter PA. *Bordetella pertussis* pathogenesis: current and future challenges. *Nat Rev Microbiol.* (2014) 12:274–88. doi: 10.1038/nrmicro3235
3. de Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR. Pertussis: a matter of immune modulation. *FEMS Microbiol Rev.* (2011) 35:441–74. doi: 10.1111/j.1574-6976.2010.00257.x
4. Tan T, Dalby T, Forsyth K, Halperin SA, Heining U, Hozbor D, et al. Pertussis across the globe. *Pediatr Infect Dis J.* (2015) 34:e222–32. doi: 10.1097/INF.0000000000000795

## DATA AVAILABILITY

All datasets generated for this study are included in the manuscript and/or the **Supplementary Files**.

## ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the Dutch Central Committee on Research involving human subjects with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol required no review by an accredited Medical Research Ethics Committee, as determined by the Dutch Central Committee on Research involving human subjects.

## AUTHOR CONTRIBUTIONS

MK, DH, H-JH, and KvB performed the experiments. MK drafted the figures. MK, RM, JvP, JdW, and EP contributed to the design of the study. MK, JvP, JdW, and EP wrote the manuscript. EP was responsible for funding. All authors approved the manuscript's final version.

## FUNDING

This work was supported by the Dutch Ministry of Health.

## ACKNOWLEDGMENTS

We would like to thank J. van Velzen for his help with the flow imaging experiment and R. Jacobi for his technical support.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.02030/full#supplementary-material>

5. van der Maas NA, Mooi FR, de Greeff SC, Berbers GA, Spaendonck MA, de Melker HE. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? *Vaccine.* (2013) 31:4541–7. doi: 10.1016/j.vaccine.2013.07.060
6. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. *Epidemiol Infect.* (2014) 142:685–94. doi: 10.1017/S0950268813000071
7. Bart MJ, van Gent M, van der Heide HG, Boekhorst J, Hermans P, Parkhill J, et al. Comparative genomics of prevaccination and modern *Bordetella pertussis* strains. *BMC Genomics.* (2010) 11:627. doi: 10.1186/1471-2164-11-627
8. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, et al. *Bordetella pertussis* strains with increased toxin production associated with pertussis resurgence. *Emerg Infect Dis.* (2009) 15:1206–13. doi: 10.3201/eid1508.081511

9. Dunne A, Ross PJ, Pospisilova E, Masin J, Meaney A, Sutton CE, et al. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against *Bordetella pertussis*. *J Immunol.* (2010) 185:1711–9. doi: 10.4049/jimmunol.1000105
10. Bernard NJ, Finlay CM, Tannahill GM, Cassidy JP, O'Neill LA, Mills KH. A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against *Bordetella pertussis*. *Mucosal Immunol.* (2015) 8:982–92. doi: 10.1038/mi.2014.125
11. Cerny O, Kamanova J, Masin J, Bibova I, Skopova K, Sebo P. *Bordetella pertussis* Adenylate Cyclase Toxin blocks induction of bactericidal nitric oxide in macrophages through cAMP-dependent activation of the SHP-1 phosphatase. *J Immunol.* (2015) 194:4901–13. doi: 10.4049/jimmunol.1402941
12. Place DE, Muse SJ, Kirimanjesswara GS, Harvill ET. Caspase-1-independent interleukin-1beta is required for clearance of *Bordetella pertussis* infections and whole-cell vaccine-mediated immunity. *PLoS ONE.* (2014) 9:9. doi: 10.1371/journal.pone.0107188
13. Awad F, Assrawi E, Jumeau C, Georgin-Lavialle S, Cobret L, Duquesnoy P, et al. Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation. *PLoS ONE.* (2017) 12:e0175336. doi: 10.1371/journal.pone.0175336
14. Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. *Immunol Rev.* (2015) 265:35–52. doi: 10.1111/immr.12286
15. Schroder K, Tschopp J. The inflammasomes. *Cell.* (2010) 140:821–32. doi: 10.1016/j.cell.2010.01.040
16. Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. *Cell.* (2014) 156:1193–206. doi: 10.1016/j.cell.2014.02.008
17. Black RA, Kronheim SR, Merriam JE, March CJ, Hopp TP. A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin-1beta. *J Biol Chem.* (1989) 264:5323–6.
18. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, et al. Activation of interferon- $\gamma$  inducing factor mediated by interleukin-1 $\beta$  converting enzyme. *Science.* (1997) 275:206–9. doi: 10.1126/science.275.5297.206
19. Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. *Cell Microbiol.* (2006) 8:1812–25. doi: 10.1111/j.1462-5822.2006.00751.x
20. Byrne P, McQuirk P, Todryk S, Mills KH. Depletion of NK cells results in disseminating lethal infection with *B. pertussis* associated with reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. *Eur J Immunol.* (2004) 34:2579–88. doi: 10.1002/eji.200425092
21. Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KHG. Atypical disease after *Bordetella pertussis* respiratory infection of mice with targeted disruptions of interferon receptor or immunoglobulin m chain genes. *J Exp Med.* (1997) 186:1843–51. doi: 10.1084/jem.186.11.1843
22. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-g genes. *Science.* (1993) 259:1739–42. doi: 10.1126/science.8456300
23. Mahon BP, Mills KHG. Interferon- $\gamma$  mediated immune effector mechanisms against *Bordetella pertussis*. *Immunol Lett.* (1999) 68:213–7. doi: 10.1016/S0165-2478(99)00070-X
24. Wawrocki S, Druszczynska M, Kowalewicz-Kulbat M, Rudnicka W. Interleukin 18 (IL-18) as a target for immune intervention. *Acta Biochim Pol.* (2016) 63:59–63. doi: 10.18388/abp.2015\_1153
25. Huang Y, Lei Y, Zhang H, Zhang M, Dayton A. Role of interleukin-18 in human natural killer cell is associated with interleukin-2. *Mol Immunol.* (2010) 47:2604–10. doi: 10.1016/j.molimm.2010.05.290
26. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN- $\gamma$  production. *J Immunol.* (1998) 161:3400–7.
27. Mavropoulos A, Sully G, Cope AP, Clark AR. Stabilization of IFN-gamma mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. *Blood.* (2005) 105:282–8. doi: 10.1182/blood-2004-07-2782
28. Thalen M, IJssel J, Jiskoot W, Zomer B, Roholl P, de Gooijer C, et al. Rational medium design for *Bordetella pertussis*: basic metabolism. *J Biotech.* (1999) 75:147–59. doi: 10.1016/S0168-1656(99)00155-8
29. Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells *in vitro*. *J Clin Invest.* (1995) 96:2578–82. doi: 10.1172/JCI118321
30. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. *Clin Exp Immunol.* (2011) 166:1–15. doi: 10.1111/j.1365-2249.2011.04440.x
31. Tartey S, Kanneganti TD. Differential role of the NLRP3 inflammasome in infection and tumorigenesis. *Immunology.* (2019) 156:329–38. doi: 10.1111/imm.13046
32. Feriotti C, de Araujo EF, Loures FV, da Costa TA, Galdino NAL, Zamboni DS, et al. NOD-Like receptor P3 inflammasome controls protective Th1/Th17 immunity against pulmonary paracoccidiodomycosis. *Front Immunol.* (2017) 8:786. doi: 10.3389/fimmu.2017.00786
33. Gross O, Poeck H, Bscheider M, Dostert C, Hanneschlagger N, Endres S, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. *Nature.* (2009) 459:433–6. doi: 10.1038/nature07965
34. van de Veerdonk FL, Joosten LA, Shaw PJ, Smeekens SP, Malireddi RK, van der Meer JW, et al. The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. *Eur J Immunol.* (2011) 41:2260–8. doi: 10.1002/eji.201041226
35. Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to *Bordetella pertussis*: towards the rational design of an improved acellular pertussis vaccine. *PLoS Pathog.* (2013) 9:e1003264. doi: 10.1371/journal.ppat.1003264
36. Fedele G, Spensieri F, Palazzo R, Nasso M, Cheung GY, Coote JG, et al. *Bordetella pertussis* commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways. *PLoS ONE.* (2010) 5:e8734. doi: 10.1371/journal.pone.0008734
37. Fedele G, Bianco M, Debie AS, Loch C, Ausiello CM. Attenuated *Bordetella pertussis* vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. *J Immunol.* (2011) 186:5388–96. doi: 10.4049/jimmunol.1003765
38. Warfel JM, Merkel TJ. *Bordetella pertussis* infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. *Mucosal Immunol.* (2013) 6:787–96. doi: 10.1038/mi.2012.117
39. da Silva Antunes R, Babor M, Carpenter C, Khalil N, Cortese M, Mentzer AJ, et al. Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters. *J Clin Invest.* (2018) 128:3853–65. doi: 10.1172/JCI121309
40. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. *Nat Immunol.* (2007) 8:942–9. doi: 10.1038/ni1496
41. Lauzon NM, Mian F, MacKenzie R, Ashkar AA. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. *Cell Immunol.* (2006) 241:102–12. doi: 10.1016/j.cellimm.2006.08.004
42. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of Toll-Like Receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J Immunol.* (2002) 168:4531–7. doi: 10.4049/jimmunol.168.9.4531
43. Hovingh ES, van Gent M, Hamstra HJ, Demkes M, Mooi FR, Pinelli E. Emerging *Bordetella pertussis* strains induce enhanced signaling of human pattern recognition receptors TLR2, NOD2 and secretion of IL-10 by dendritic cells. *PLoS ONE.* (2017) 12:e0170027. doi: 10.1371/journal.pone.0170027
44. Brummelman J, Veerman RE, Hamstra HJ, Deuss AJ, Schuijt TJ, Sloots A, et al. *Bordetella pertussis* naturally occurring isolates with altered lipooligosaccharide structure fail to fully mature human dendritic cells. *Infect Immun.* (2015) 83:227–38. doi: 10.1128/IAI.02197-14
45. Nathan CF, W. MH, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. *J Exp Med.* (1983) 158:670–89. doi: 10.1084/jem.158.3.670
46. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, et al. Vitamin D is required for IFN-g-mediated antimicrobial activity of human macrophages. *Science Transl Med.* (2011) 3:104ra102. doi: 10.1126/scitranslmed.3003045

47. Lamberti YA, Hayes JA, Perez Vidakovics ML, Harvill ET, Rodriguez ME. Intracellular trafficking of *Bordetella pertussis* in human macrophages. *Infect Immun.* (2010) 78:907–13. doi: 10.1128/IAI.01031-09
48. Walch M, Dotiwala F, Mulik S, Thiery J, Kirchhausen T, Clayberger C, et al. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes. *Cell.* (2014) 157:1309–23. doi: 10.1016/j.cell.2014.03.062
49. Dotiwala F, Sen Santara S, Binker-Cosen AA, Li B, Chandrasekaran S, Lieberman J. Granzyme B disrupts central metabolism and protein synthesis in bacteria to promote an immune cell death program. *Cell.* (2017) 171:1125–37 e11. doi: 10.1016/j.cell.2017.10.004

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Kroes, Mariman, Hijdra, Hamstra, van Boxtel, van Putten, de Wit and Pinelli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.